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Abstract
AIM: To investigate whether amifostine contributes to 
the antioxidant and cytoprotective effects of histidine-
tryptophan-ketoglutarate (HTK) and University of Wis-
consin (UW) preservation solutions.
METHODS: Forty-eight Sprague Dawley male rats 
were equally divided into six groups: (1) ringer Lactate 
(RL) group; (2) RL + amifostine (RL + A) group; (3) 
HTK group; (4) HTK + A group; (5) UW group; and (6) 
UW + A group. Rats in the RL + A, HTK + A and UW + 
A groups were administered amifostine intraperitone-
ally at a dose of 200 mg/kg prior to laparotomy. The RL 
group was perfused with RL into the portal vein. The RL 
+ A group were perfused with RL into the portal vein 
after amifostine administration. The HTK group received 
an HTK perfusion while the HTK + A group received an 
HTK perfusion after administration of amifostine. The 
UW group received a perfusion of UW, while the UW + 
A group received a UW perfusion after amifostine ad-
ministration. Liver biopsy was performed to investigate 
histopathological, immunochemical [transferase medi-
ated dUTP nick end labeling (TUNEL), inducible nitric 
oxide syntetase (iNOS)] and ultrastructural alterations. 
Biochemical alterations were determined by examining 
levels of alanine aminotransferase, alkaline phosphatase 
and nitric oxide in the perfusion fluid. 
RESULTS: Pathological sinusoidal dilatation and centri-
lobular hydropic alteration were significantly lower in the 
groups that received amifostine prior to preservation so-
lution perfusion. Although the best results were obtained 
in the UW + A group, we did not observe a statistically 
significant difference between the UW + A and HTK + A 
groups. iNOS grades were significantly lower in the ami-
fostine groups 12 h after treatment. When the amifos-
tine groups were compared against each other, the iNOS 
grades obtained from the UW + A and HTK + A groups 
were similar while the RL + A group had a much poorer 
score. TUNEL assays demonstrated a lower apoptosis 
ratio in the amifostine groups than in the non-amifostine 
groups 12 h after treatment. No statistically significant 
difference was observed between the UW + A and HTK 
+ A groups for apoptosis. Cellular ultrastructure was best 
preserved in the UW + A and HTK + A groups.
CONCLUSION: Here, we show that preoperative ad-
RANDOMIZED CONTROLLED RIAL
ministration of a single dose of amifostine is sufficient 
to minimize the preservation damage in hepatic cells.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Preserving liver tissue obtained from a donor 
until implantation is a critical step that affects how the 
graft will function. Many different organ preservation 
solutions have been introduced over the last quarter 
century, and histidine-tryptophan-ketoglutarate (HTK) 
and University of Wisconsin (UW) are currently the 
most commonly used solutions in clinical practice. Be-
cause neither the HTK nor UW solution is ideal, many 
studies have focused on methods to enhance the anti-
oxidant and cytoprotective effects of the preservation 
solutions. In this study, we investigated whether ami-
fostine could boost the antioxidant and cytoprotective 
effects of HTK and UW preservation solutions.
Akbulut S, Sevmis S, Karakayali H, Bayraktar N, Unlukaplan M, 
Oksuz E, Dagdeviren A. Amifostine enhances the antioxidant and 
hepatoprotective effects of UW and HTK preservation solutions. 
World J Gastroenterol 2014; 20(34): 12292-12300  Available 
from: URL: http://www.wjgnet.com/1007-9327/full/v20/
i34/12292.htm  DOI: http://dx.doi.org/10.3748/wjg.v20.i34.12292
INTRODUCTION
Preserving liver tissue harvested from a living or deceased 
donor under ideal conditions until the time of  transplan-
tation a critical step that ultimately determines whether 
the graft will be functional in the host. Because a liver to 
be transplanted is often transported over a long distance, 
the prolonged cold ischemia process highlights the critical 
role played by the preservation process. In organ preserva-
tion, the primary goals are to establish hypothermia, pre-
vent cellular swelling, and minimize free radical-induced 
ischemia-reperfusion injuries. Although many preserva-
tion solutions have been published over the last quarter 
century, the University of  Wisconsin (UW) and histidine-
tryptophan-ketoglutarate (HTK) solutions are most 
widely used clinically[1-5]. Preservations solutions contain a 
variety of  substances to prevent cellular swelling, stabilize 
cell membranes, exert antioxidant and cytoprotective ef-
fects, and maintain intracellular electrolyte levels. The UW 
preservation solution uses adenosine, glutathione, and 
allopurinol as antioxidant and cytoprotective agents while 
the HTK solution utilizes histidine, tryptophan, ketoglu-
tarate, and mannitol[5]. A current focus in the transplant 
field is to enhance the antioxidant and cytoprotective ef-
fects of  preservation solutions.Amifostine (WR-2721) is 
an antioxidant and cytoprotective agent that can scavenge 
for and eliminate free oxygen radicals and reactive nucleo-
philes known to cause DNA damage and injury[6-8]. Like 
other published antioxidants, amifostine derives its antiox-
idant potential from a thiol molecular structure. The pres-
ence of  intracellular free thiols has been shown to reduce 
oxidative stress and thus minimize apoptosis and DNA 
injury[6-8]. The aim of  the present study was to determine 
whether preoperative administration of  amifostine would 
enhance the antioxidant and cytoprotective effects of  
HTK and UW preservation solutions. 
MATERIALS AND METHODS
The Baskent University Ethics Committe for Animal 
Research approved this research (No. DA07/45). All 
experimental procedures within this manuscript were 
in compliance with the guidelines established by the 
National Institutes of  Health within the “Guide for the 
Care and Use of  Laboratory Animals”. Forty-eight adult 
male Sprague Dawley rats (mean weight: 300-350 g) were 
used for these experiments. The 48 rats were randomly 
assigned to one of  six groups, with an equal number 
of  rats contained within each group. The six groups 
were as follows: Group-Ⅰ: Ringer Lactate (RL) group; 
Group-Ⅱ: RL + amifostine (RL + A) group; Group-
Ⅲ: HTK group; Group-Ⅳ: HTK + A group; Group-V: 
UW group; Group-Ⅵ: UW + A group. Rats were given 
50 mg/kg ketamine hydrochloride (Ketalar, Eczacibasi 
Warner-Lambert, Levent, İstanbul, Turkey) and 10 mg/
kg xylazine hydrochloride (Rompon, Bayer, Sisli, İstanbul, 
Turkey) prior to all surgical procedures. Rats in groups 
Ⅱ, Ⅳ, and Ⅵ were administered amifostine 200 mg/kg 
(Ethyol, Medimmune Pharma B.V., the Netherlands) 
intraperitoneally 30 min prior to the laparotomy. After 
confirming that the rats were adequately anesthetized, 
a laparotomy was performed via a midline incision. 
The distal part of  the portal pedicle was ligated after 
a cannula was placed in the portal vein lumen. Group-
Ⅰ rats were perfused with RL preserved at 4 ℃ solution 
through the cannula into the portal vein. Group-Ⅱ rats 
were administered amifostine before the laparotomy 
and then subsequently perfused with RL, like the rats in 
Group-Ⅰ. Rats in Group-Ⅲ were perfused with HTK 
(Custodiol; Odyssey Pharmaceutical Inc., East Hanover, 
NJ, United States) preserved at 4 ℃. Group-Ⅳ rats were 
first infused with amifostine before laparotomy, followed 
by perfusion with HTK. Rats in Group-V were perfused 
with UW solution (Viaspan; DuPont Merck Pharmaceuti-
cal Company, Wilmington, DE, United States) preserved 
at 4 ℃. Rats in Group-Ⅵ received amifostine prior to the 
laparotomy and were subsequently perfused with UW. 
During the perfusion process, the suprahepatic vena cava 
was cut to determine if  the fluid draining from the liver 
was clear. The perfusion process was continued until the 
drained fluid became clear. After perfusion, a standard 
hepatectomy was performed. Isolated liver specimens 
were placed into bags containing RL, UW, or HTK solu-
tions and stored in ice-filled storage boxes. At 0, 6, and 
12 h post-hepatectomy (PH), biopsy samples were taken 
from the stored liver tissues for pathological and immu-
nohistochemical evaluation, and fluid samples were taken 
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for biochemical analysis. A liver biopsy was also taken 6 h 
PH for analysis by electron microscopy. 
Pathological and immunohistochemical evaluations 
Evaluation of  hepatocyte injury with hematoxylin 
and eosin: To determine if  hepatocyte injury occurred 
during the preservation process, hematoxylin and eosin 
staining were used to assay four different parameters: 
fatty change (FC; absent or present: 1%-30%, 31%-60%, 
61%-100%), hepatocyte ballooning degeneration (BD; 
absent or present: mild, moderate and severe), centrilobu-
lar hydropic change (CLHC; absent or present: focal or 
diffuse), and sinusoidal dilatation (SD; absent or present: 
focal or diffuse)[1,9].
Semi-quantitative evaluation of  hepatocytes with 
inducible nitric oxide syntetase (iNOS) staining: Tis-
sues were embedded in paraffin. Tissue cross-sections (3 
µm thickness) were stained with iNOS and examined un-
der microscope. Hepatocyte iNOS staining was scored as 
follows: Grade 0: less than 10% of  hepatocytes stained; 
Grade Ⅰ: 10%-25% of  hepatocytes stained; Grade Ⅱ: 
25%-50% of  hepatocytes stained; and Grade Ⅲ: more 
than 50% of  hepatocytes stained[10,11].
Evaluation of  hepatocyte apoptosis: Three micron 
cross-sections from paraffin-embedded tissues were 
analyzed for apoptosis using terminal deoxynucleotidyl 
transferase mediated dUTP nick end labeling (TUNEL). 
TUNEL-processed tissues were analyzed in at least 10 
different fields of  view under a × 400 magnification, with 
at least 1000 hepatocytes counted. The number of  cells 
with TUNEL-positive nuclei were recorded[12,13].
Ultrastructural changes
Liver specimens from four rats, randomly selected from 
each group, were treated with certain biochemical pro-
cesses and examined under LEO 906E transmission 
electron microscopy. Changes in nuclei, endothelial 
cells, plasma membrane, mitochondria, and endoplasmic 
reticulum ultrastructure were examined by electron mi-
croscopy[1]. The results were evaluated by an experienced 
histologist. 
Biochemical parameters
Alanine aminotransferase (ALT) was analyzed by an Ul-
traviolet (UV) absorbance method that had been adapted 
to a standardized method while alkaline phosphatase 
(ALP) was analyzed using a colorimetric approach. The 
levels both enzyme were expressed in unit/liter (U/L). 
Nitric oxide (NO) concentration was analyzed using the 
nitrate/nitrite colorimetric test kit (Cayman chemical, 
Ann Arbor, MI, United States), with an absorbance of  
550 nm. The results were presented as µm/mL[14].
Statistical analysis
All results from this study were analyzed with SPSS 11.5 
statistical software (IBM, Chicago, IL, United States). 
Intergroup comparisons were performed with student’s t 
test, χ 2 test, and ANOVA. A P value < 0.05 was set as the 
threshold for statistical significance. Where appropriate, 
the results presented in tables are displayed as the mean 
± SD.
RESULTS
Evaluation of liver parenchyma histopathology
Liver biopsy samples stained with hematoxylin and eosin 
were examined to determine if  FC, BD, CLHC, or SD 
pathological hepatocyte injuries occurred (Figure 1). A 
significant difference was observed between the RL and 
RL + A groups with respect to CLHC at 6 and 12 h PH (P 
< 0.05 for both time points). HTK and HTK + A groups 
were significantly different with regard to both SD (6 h 
PH: P = 0.05; 12 h PH: P < 0.05) and CLHC (6 h PH: P 
< 0.04; 12 h PH: P = 0.05). UW and UW + A groups had 
significantly different SD (P < 0.05 at both time points) 
and CLHC (P < 0.05 at both time points). When examin-
ing the amifostine-treated groups, the UW + A group had 
the best results although a statistically significant differ-
ence was not observed from the HTK + A group. Rats in 
the RL + A group displayed more prominent pathological 
changes in SD and CLHC when compared to the other 
amifostine-treated groups. FC and BD histology was un-
changed between the groups. The results are summarized 
in Table 1.
Evaluation of cell death in preserved tissues 
The results of  TUNEL assays used to evaluate cell death 
under the different preservation conditions are summa-
rized in Table 2. During the first six hours PH, no signifi-
cant differences in cell death were observed across any of  
the treatment groups. At 12 h PH, however, there was a 
significant reduction in apoptosis in groups that had been 
pre-treated with amifostine. When the non-amifostine 
groups were compared, the RL alone group had a signifi-
cantly higher rate of  apoptosis (P < 0.04), while HTK and 
UW groups did not significantly differ from each other 
(P < 0.25). Similarly, in the amifostine-treated groups, the 
RL+A had a significantly higher rate of  apoptosis while 
there was no appreciable difference between the UW + A 
and HTK + A groups. 
Evaluation of iNOS
iNOS-stained samples were graded semi-quantitatively as 
0, Ⅰ, Ⅱ, and Ⅲ (described in the materials and methods 
section). The amifostine-treated groups received lower 
iNOS grades than the non-amifostine groups, a differ-
ence that became statistically significant at 12 h PH. 
Within the amifostine-treated groups, no significant dif-
ferences were observed for the UW + A and HTK + A 
groups, while the RL + A group had a significantly worse 
grade. The findings are summarized in Table 3. 
Evaluation of NO levels 
NO levels from perfusion fluids were measured biochem-
ically at 0, 6, and 12 h PH. Intergroup analyses showed 
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group while the highest levels were observed in the RL 
group (RL vs RL + A: not significant; UW vs UW + A: P 
< 0.02; HTK vs HTK + A: P < 0.045). During the first 6 
h PH, ALP levels were not statistically different between 
the groups. The lowest ALP levels were observed in the 
UW + A group while the highest levels were observed in 
the RL group. No significant differences existed between 
HTK + A and UW + A groups. The results are summa-
that the UW+A group had the lowest NO levels while 
the RL group showed the highest NO levels at all time 
points examined. The amifostine-treated groups generally 
had lower NO levels than the other groups. The findings 
are summarized in Table 4. 
Evaluation of ALT and ALP levels
The lowest ALT levels were observed in the UW + A 
12295 September 14, 2014|Volume 20|Issue 34|WJG|www.wjgnet.com
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Figure 1  Pathological changes observed after tissue preservation. A: Hepatocyte ballooning degeneration, × 200 magnification; B: Centrilobular hydropic 
change, × 400 magnification; C: Microvesicular fatty change, × 400 magnification; D: Sinusoidal dilatation, × 400 magnification.
Table 1  Pathological changes after hepatectomy
Groups Time n SD CLHC BD FC
(+) (-) (+) (-) (+) (-) (+) (-)
RL   0 h 8 1 7 2 6 1 7 0 8
  6 h 8 2 6 4 4 2 6 0 8
12 h 8 5 3 7 1 4 4 1 7
RL + A   0 h 8 2 6 2 6 0 8 0 8
  6 h 8 1 7 0 8 2 6 0 8
12 h 8 3 5 4 4 2 6 0 8
HTK   0 h 8 1 7 0 8 0 8 1 7
  6 h 8 4 4 4 4 1 7 0 8
12 h 8 3 5 4 4 2 6 1 7
HTK + A   0 h 8 0 8 0 8 0 8 0 8
  6 h 8 2 6 1 7 0 8 0 8
12 h 8 1 7 2 6 1 7 1 7
UW   0 h 8 1 7 0 8 0 8 0 8
  6 h 8 4 4 4 4 0 8 1 7
12 h 8 3 5 3 5 1 7 1 7
UW + A   0 h 8 0 8 0 8 0 8 0 8
  6 h 8 1 7 1 7 0 8 0 8
12 h 8 1 7 1 7 0 8 0 8
SD: Sinusoidal dilatation; CLHC: Centrilobular hydropic change; BD: Hepatocyte balooning degeneration; FC: Fatty change; RL + A: Ringer Lactate + 
amifostine; HTK: Histidine-tryptophan-ketoglutarate; UW: University of Wisconsin.
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rized in Table 5. 
Evaluation of histological findings with transmission 
electron microscopy 
Evaluation of  the cellular ultrastructure across the six 
groups revealed that the UW + A group were best pre-
served, resembling a control liver sample (Figure 2A and 
B). The HTK + A, UW and RL + A groups had an in-
termediate preservation phenotype, with some ultrastruc-
tural damage (Figure 2C), while the HTK and RL groups 
were poorly preserved (Figure 2D). Some hepatocytes in 
each group contained lipid droplets, though it may be at-
tributed more too external factors such as diet. 
DISCUSSION
To appreciate the substantial advances made in the field 
of  organ transplantation, it is first necessary to briefly 
discuss its history. The first experimental liver transplan-
tation in the world was performed by Welch in 1955 
while the first human liver transplantation was performed 
by Starzl in 1963[15]. Starzl’s first several attempts at liver 
transplantation failed, until he achieved success in 1967. 
Bismuth et al[16] developed the first protocol for reduced-
size liver transplantation in 1984. The first ex situ split 
liver transplantation was performed by Pichlmayr et al[17] 
in 1988 while the first living donor liver transplantation 
was successfully completed by Strong et al[18] in 1989. In 
Turkey, the first deceased donor liver transplantation was 
performed by Haberal et al in 1988. Karakayali et al[19] 
and Haberal et al[20,21] also successfully performed the first 
pediatric segmental living donor liver transplantation in 
Europe and the Middle East in 1990. That same year, the 
same team announced the first segmental adult living do-
nor liver transplantation in the world.
After Busuttil et al[15] successfully performed a liver 
transplant, liver transplantation has become the standard 
therapy for end-stage liver disease and acute liver failure. 
Despite the recent advances in surgical techniques, inten-
sive care unit facilities, and immunosuppressive therapies, 
graft failure still occurs during the postoperative period 
and, due to a shortage of  donors, many patients are un-
able to survive long enough for retransplantation[22]. The 
term “Primary non-function” (PNF) has been developed 
to describe the clinical entity characterized by postopera-
tive serum liver enzyme elevation, decreased bile produc-
tion, and severe coagulopathy. Many factors such as poor 
surgical technique, poor graft quality, prolonged cold 
ischemia, ischemia-reperfusion injury, and preservation 
injury, have been implicated in inciting PNF during the 
postoperative period[1,5,23-25].
The process of  organ preservation begins when a 
donor patient is diagnosed as brain dead or at a donor’s 
operation for organs from living donor origin. The pro-
cess ends when vascular anastomosis is complete and the 
organ is fully functional. Once tissue blood flow ceases, 
oxidative phosphorylation mechanisms become impaired, 
intracellular ATP is reduced, and marked increases in 
AMP levels are observed in cells exposed to ischemia. 
The resultant increases in AMP follows the hypoxan-
thine, xanthine, and urea pathway in oxygenated medium, 
using molecular oxygen instead of  NAD+ as the electron 
acceptor in non-oxygenated media, which ultimately leads 
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Table 2  Distribution of apoptotic cells detected with terminal 
deoxynucleotidyl transferase mediated dUTP nick end labeling 
staining
Groups n 0 h 6 h 12 h
RL 8 148 ± 26 185 ± 22 229 ± 41
RL + A 8 144 ± 25 166 ± 24 172 ± 24
P value 0.40 0.36 0.05
HTK 8 111 ± 30 144 ± 46 169 ± 42
HTK + A 8 101 ± 19 126 ± 16 133 ± 14
P value 0.45 0.45 0.04
UW 8 100 ± 23 115 ± 25 158 ± 24
UW + A 8 90 ± 16 100 ± 21 116 ± 18
P value 0.42 0.44 0.01
Table 3  Intergroup comparisons after inducible nitric oxide 
syntetase grading
Time G RL RL + A HTK HTK + A UW UW + A
n = 8 n  = 8 n  = 8 n  = 8 n  = 8 n  = 8
0  h 0 0 3 4 4 7 6
Ⅰ 3 2 2 4 0 1
Ⅱ 3 2 2 0 1 1
Ⅲ 2 1 0 0 0 0
P value 0.590 0.26 0.24
6 h 0 0 1 1 3 1 4
Ⅰ 4 0 5 4 6 3
Ⅱ 4 6 2 1 1 1
Ⅲ 0 1 0 0 0 0
P value 0.055 0.02 0.51
12 h 0 1 1 0 2 0 2
Ⅰ 0 2 1 4 3 5
Ⅱ 1 4 5 1 3 1
Ⅲ 6 2 2 1 2 0
P value 0.030 0.05 0.04
N: Number of rats; G: Inducible nitric oxide syntetase grade; RL + A: 
Ringer Lactate + amifostine; HTK: Histidine-tryptophan-ketoglutarate; 
UW: University of Wisconsin.
Table 4  Intergroup comparison of nitric oxide levels in liver 
preservation solutions
Groups n 0 h 6 h 12 h
RL 8 0.79 ± 0.22 1.15 ± 0.24 1.78 ± 0.26
RL + A 8 0.73 ± 0.18 1.26 ± 0.18 1.34 ± 0.23
P value 0.690 0.61 0.022
HTK 8 0.64 ± 0.19 1.09 ± 0.19 1.71 ± 0.15
HTK + A 8 0.71 ± 0.19 0.80 ± 0.10 1.04 ± 0.13
P value 0.590 0.06 0.016
UW 8 0.81 ± 0.18 1.02 ± 0.34 1.31 ± 0.98
UW + A 8 0.46 ± 0.21 0.60 ± 0.14 0.69 ± 0.13
P value 0.033 0.01 0.020
Akbulut S et al . Antioxiadant and cytoprotective effects of amifostine
RL + A: Ringer Lactate + amifostine; HTK: Histidine-tryptophan-ketoglu-
tarate; UW: University of Wisconsin.
RL + A: Ringer Lactate + amifostine; HTK: Histidine-tryptophan-ketoglu-
tarate; UW: University of Wisconsin.
to the production of  anion radicals and hydrogen per-
oxide[26-28]. The fundamental goals of  liver preservation 
from a deceased or a living donor are to keep the organ 
hypothermic, prevent cellular swelling, and minimize free 
radical-induced injury until the organ is functioning nor-
mally again. Although hundreds of  preservation solutions 
have been developed over the last quarter century to 
facilitate a more successful transplant process, the HTK 
and UW solutions are most commonly used in clinical 
practice. Both solutions contain electrolytes that help 
maintain the osmotic equilibrium of  the cell as well as 
membrane-stabilizing agents and antioxidants that scav-
enge free oxygen radicals produced during the ischemic 
period[1-5,29,30].
UW solution was developed by Belzer et al at the 
University of  Wisconsin. It contains glutathione, which 
prevents free radical formation, allopurinol, raffinose, ad-
enosine for ATP production, hydroxyethyl starch to pre-
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Table 5  Alanine aminotransferase and alkaline phosphatase levels after hepatectomy
Groups 0 h 6 h 12 h
ALP ALT ALP ALT ALP ALT
RL 2.6 ± 1.9 17.6 ± 9.8 55.9 ± 7.5   90.4 ± 16.2 82.1 ± 7.8   370.1 ± 73.8
RL + A 1.9 ± 0.8 15.8 ± 7.4 25.0 ± 3.3   84.4 ± 14.1 44.0 ± 6.0   309.5 ± 46.1
HTK 1.1 ± 0.3 19.4 ± 6.4 33.1 ± 6.2 60.6 ± 7.1 50.4 ± 6.5   172.6 ± 22.5
HTK + A 1.9 ± 1.3 23.4 ± 8.4 25.4 ± 3.5 41.4 ± 2.8 35.3 ± 4.2 110.9 ± 9.8
UW 1.3 ± 0.4 27.8 ± 7.5 32.0 ± 4.6 59.1 ± 5.9 46.9 ± 6.2   188.3 ± 76.5
UW + A 2.1 ± 2.2 16.6 ± 5.1 22.6 ± 5.3 41.6 ± 6.6 28.3 ± 5.6   80.0 ± 7.5
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Figure 2  Electron micrographs of liver ultrastructure from different preservation conditions. A: Hepatocyte from a normal rat. The nucleus (n = Ç) is rich in 
euchromatin and has a prominent nucleolus (n = ç). The cytoplasm is full of organelles and contains rough endoplasmic reticulum (GER), multiple mitochondria (m), 
and several peroxisomes (p); B: Low magnification micrograph of a UW + A group liver showing a sinusoid and surrounding hepatocytes. Sinusoidal endothelium (ar-
rows) and microvilli in Disse’s space (Ds) are present, with a reticular fiber bundle in Disse’s space next to the arrow on the right. In addition to GER and smooth ER, 
several peroxisomes (p) and autophagic vacuoles (Ov) are visible in the cytoplasm of the mitochondria-rich hepatocytes. Indistinct microvilli and excessively dilated 
bile canaliculi (*) are also apparent, though the fine structure is preserved overall; C: Low magnification micrograph from the HTK + A group shows hepatocytes and 
sinusoids full of granulated material, containing one erythrocyte. Mitochondria (m) and peroxisomes (p) are evident, with patchy cisternae of GER scattered between. 
Membranous structures were not clearly distinguished around the sinusoid. Multiple autophagic vacuoles containing degenerated organelles (arrowheads) are visible 
in the cytoplasm. A bile canaliculus has a dilated lumen and there is moderate/weak preservation of fine structures; D: Micrograph of hepatocytes from the RL group. 
The nucleus (N) of the middle hepatocyte is rich in euchromatin and its nucleolus is observed. In addition to the organelles found in the control group, the cytoplasm 
contains a few lipid droplets. The presence of GER is prominent at the perinuclear region of the cell. In addition to multiple mitochondria, more organelles with degen-
erative changes are observed when compared to the control group. 
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ALP: Alkaline phosphatase; ALT: Alanine Aminotransferase; RL + A: Ringer Lactate + amifostine; HTK: Histidine-tryptophan-ketoglutarate; UW: 
University of Wisconsin.
Ov
S
vent interstitial edema, and phosphate ions for pH stabili-
zation. Because of  the high potassium content, however, 
UW solution can lead to hyperkalemia onset. Compared 
to HTK solution, UW preservation solution has a higher 
viscosity and more prominent endothelium-protective 
properties. In contrast, its ischemic biliary complication 
rates are much higher than the HTK solution. UW solu-
tion also increases hepatic artery resistance and enhances 
erythrocyte aggregation, which are undesirable features in 
a preservation solution[1,5,30]. 
HTK solution, an extracellular protective solution, 
was initially developed to treat cardioplegia in the 1980s. 
In this solution, the mannitol and histidine components 
exert both antioxidant and osmotic effects. Ketoglutarate 
and tryptophan, two other primary components in HTK, 
are both membrane-protective agents; ketoglutarate 
also acts as a substrate in the Krebs cycle in an oxygen-
deprived cell. Because HTK contains low amounts of  
K+ and Na++, it was initially widely used during cardiac 
transplantation. The HTK solution has a lower viscosity 
and promotes more rapid cooling of  organs, with a flow 
rate three times higher than other preservation solutions. 
Compared to UW, HTK is more affordable and poses 
no risk for hyperkalemia when used in flushing mode. 
In general, the HTK solution reduces leukocyte adhe-
sion, capillary permeability, and ATP consumption while 
increasing tissue oxygenation and LDH levels. Previous 
studies have demonstrated that HTK is as efficient as 
UW in liver preservation[2,3,5,30]. Mangus et al[3] reported no 
difference between liver transplantation groups that re-
ceived HTK or UW with respect to graft survival, patient 
survival, PNF development, and postoperative complica-
tions. The same research group also reported that HTK, 
when compared to UW, allowed for more rapid cooling 
and cleared blood from the organ more rapidly and more 
efficiently. UW, on the other hand, was shown to more 
efficiently preserve grafts with longer cold ischemia time. 
The same authors reported in a separate study that biliary 
complications and overall costs were lower with HTK[4]. 
Moray et al[2] reported no difference between the HTK 
and UW groups with respect to complication rates but 
added that HTK was more cost-efficient. In the present 
study, ALP was examined biochemically and bile cana-
liculi were examined histopathologically to evaluate the 
biliary system. No significant difference was detected be-
tween the amifostine-treated groups with regard to ALP 
level. Histopathology of  the samples, however, demon-
strated that cell frame (i.e., structure of  bile canaliculi) 
was better preserved in the UW + A group. 
Amifostine (WR-2721) is an inorganic thiophosphate 
compound weighing 214 kDa. Amifostine is dephosphor-
ylated by the membrane-bound enzyme alkaline phospha-
tase and internalized through the cell membrane. Once 
inside the cell, amifostine is converted to its active form, 
the metabolite WR-1065, which stabilizes the membrane 
of  intracellular organelles and protects cells against cyto-
toxic agents. Amifostine eliminates free oxygen radicals 
formed during ionizing radiation, or by chemicals such 
as anthracycline and bleomycin. Thus, amifostine is an 
antioxidant and cytoprotective agent that is capable of  
eliminating free oxygen radicals. Healthy cells have higher 
alkaline phosphatase activity while hypoxic and cancer 
cells, which have altered membrane lipid structure, have 
substantially lower enzymatic activity. Thus, amifostine 
administration is required prior to the development of  
cellular injury. If  amifostine is administered after cellular 
damage has already occurred, it is unable enter the cell or 
be converted to its active metabolite, WR-1065. Clinical 
studies with amifostine have administered it intravenously 
30 min prior to radiotherapy. For rats, the recommended 
dose is 200 mg/kg given subcutaneously, though studies 
have demonstrated that intravenous and subcutaneous 
administration result in the same drug efficacy[6-8]. In our 
study, three amifostine-treated groups were compared to 
three non-amifostine-treated groups. Biochemical analy-
ses revealed that all three amifostine-treated groups had 
lower ALT and ALP levels, as well as less vacuolization 
and reduced bile canaliculi injury and epithelial degenera-
tion in the sinusoidal epithelium. Immunohistochemical 
analyses revealed less overall cellular injury in groups that 
received amifostine. Taken together, these results demon-
strate the robust protective effect exerted by amifostine.
Hepatic injury is readily observed through biochemi-
cal, histopathological, immunohistochemical or ultra-
structural approaches. Atık et al[10] observed a strong 
correlation between the extent of  cellular injury and the 
induced expression of  iNOS. Further, Romero et al[11] 
demonstrated a correlation between the severity of  cel-
lular injury in transplant rejection and the iNOS staining 
grade. In our study, less iNOS staining (and thus a lower 
grade) was evident in groups treated with amifostine, 
especially 12 h PH. These results support the hypothesis 
that amifostine reduces hepatocyte injury during cold 
preservation. 
Kuo et al[31], using a TUNEL approach to examine cell 
death, showed that cold preservation-induced cell damage 
caused cell death, primarily through apoptosis. Natori et 
al[32] reported that although caspase-dependent apoptosis 
was evident in sinusoidal epithelial cells during the cold 
ischemia period, hepatocyte damage was rarely observed. 
Using a TUNEL approach, Natori et al[32] also showed 
that provision of  caspase inhibitors protected endothelial 
cells against apoptosis. In our study, administration of  
amifostine resulted in significantly lower apoptosis rates 
when compared to the non-amifostine groups. 
In conclusion, studies to identify the best preserva-
tion solution and technique to minimize cold ischemia 
injury and preserve cadaveric livers are essential for bet-
ter success in transplantation procedures. In the present 
study, we showed that a single dose of  amifostine during 
the preoperative period minimized preservation injury in 
hepatic cells. 
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and acute liver failure. Despite several recent advances in surgical techniques, 
intensive care unit facilities, and immunosuppressive therapies, there is still an 
appreciable rate of graft failure during the postoperative period. Many factors, 
such as prolonged cold ischemia, preservation injury and ischemia-reperfusion 
injury, have been implicated in graft failure. 
Research frontiers
The process of organ preservation begins when a donor patient is diagnosed 
as brain dead or at a donor’s operation for organs from living donor origin. The 
process ends when vascular anastomosis is complete and the organ is fully 
functional. Organ preservation is a critical step in determining successful en-
graftment. Although many organ preservation solutions have been introduced 
in the last quarter century, the University of Wisconsin (UW) and histidine-tryp-
tophan-ketoglutarate (HTK) solutions are most widely used clinically. Despite 
these advances, the search for ideal preservation conditions is still ongoing. 
One way to overcome this obstacle is to provide antioxidant agents to the HTK 
and UW solutions.
Innovations and breakthroughs
The primary aim of this study was to investigate whether amifostine contributed 
to the antioxidant and cytoprotective effects of HTK and UW preservation solu-
tions. No studies exist on the combined therapy of amifostine and UW or HTK 
solutions. 
Terminology
UW solution was developed for graft preservation from either a living or de-
ceased donor. UW solution contains components such as glutathione to prevent 
free radical formation, adenosine for ATP production, hydroxyethyl starch for 
preventing interstitial edema, and phosphate ions for pH stabilization. The HTK 
solution was initially developed for cardioplegia in the 1980s. In this solution, 
mannitol and histidine exert antioxidant and osmotic effects. The ketoglutarate 
and tryptophan components, on the other hand, are membrane-protective 
agents while ketoglutarate additionally acts as a substrate of the Krebs cycle 
in an oxygen-deprived cell. Amifostine is an antioxidant and cytoprotective 
agent that can scavenge for and eliminate free oxygen radicals and reactive 
nucleophiles, which are known to cause DNA injury. The antioxidant properties 
of amifostine are due to its thiol structure.
Peer review
In the manuscript: Antioxiadant and cytoprotective effect of amifostine, Akbulut 
et al have examined the protective effect of amifostine in preservation of liver 
in combination with known protective agents. The results are well represented 
and define the suitability of amifostine along with HTK and UW preservation 
solutions.
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